Abstract

The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as a dependency transcription factor in adrenergic neuroblastoma based on recurrent chromosome 2p focal gains and amplifications, specific expression in the normal sympatho-adrenal lineage and adrenergic neuroblastoma, regulation by multiple adrenergic specific (super-)enhancers and strong dependency on high SOX11 expression in adrenergic neuroblastomas. SOX11 regulated direct targets include genes implicated in epigenetic control, cytoskeleton and neurodevelopment. Most notably, SOX11 controls chromatin regulatory complexes, including 10 SWI/SNF core components among which SMARCC1, SMARCA4/BRG1 and ARID1A. Additionally, the histone deacetylase HDAC2, PRC1 complex component CBX2, chromatin-modifying enzyme KDM1A/LSD1 and pioneer factor c-MYB are regulated by SOX11. Finally, SOX11 is identified as a core transcription factor of the core regulatory circuitry (CRC) in adrenergic high-risk neuroblastoma with a potential role as epigenetic master regulator upstream of the CRC.

The development of neuroblastoma (NB) is regulated by multiple core transcription factors. Here, SOX11 is identified as a potential epigenetic master regulator upstream of the core regulatory circuitry in adrenergic high-risk neuroblastoma.

Details

Title
SOX11 regulates SWI/SNF complex components as member of the adrenergic neuroblastoma core regulatory circuitry
Author
Decaesteker, Bieke 1   VIAFID ORCID Logo  ; Louwagie, Amber 1   VIAFID ORCID Logo  ; Loontiens, Siebe 1   VIAFID ORCID Logo  ; De Vloed, Fanny 1   VIAFID ORCID Logo  ; Bekaert, Sarah-Lee 1   VIAFID ORCID Logo  ; Roels, Juliette 1   VIAFID ORCID Logo  ; Vanhauwaert, Suzanne 1   VIAFID ORCID Logo  ; De Brouwer, Sara 1 ; Sanders, Ellen 1 ; Berezovskaya, Alla 2 ; Denecker, Geertrui 1 ; D’haene, Eva 1 ; Van Haver, Stéphane 3 ; Van Loocke, Wouter 1 ; Van Dorpe, Jo 4   VIAFID ORCID Logo  ; Creytens, David 4 ; Van Roy, Nadine 1 ; Pieters, Tim 1 ; Van Neste, Christophe 1   VIAFID ORCID Logo  ; Fischer, Matthias 5   VIAFID ORCID Logo  ; Van Vlierberghe, Pieter 1   VIAFID ORCID Logo  ; Roberts, Stephen S. 6 ; Schulte, Johannes 7   VIAFID ORCID Logo  ; Ek, Sara 8   VIAFID ORCID Logo  ; Versteeg, Rogier 9   VIAFID ORCID Logo  ; Koster, Jan 9   VIAFID ORCID Logo  ; van Nes, Johan 9 ; Zimmerman, Mark 2   VIAFID ORCID Logo  ; De Preter, Katleen 1   VIAFID ORCID Logo  ; Speleman, Frank 1   VIAFID ORCID Logo 

 Ghent University, Department of Biomolecular medicine, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); Cancer Research Institute Ghent (CRIG), Ghent, Belgium (GRID:grid.510942.b) 
 Dana-Farber Cancer Institute, Department of Pediatric Oncology, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910) 
 Ghent University, Department of Biomolecular medicine, Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798); Cancer Research Institute Ghent (CRIG), Ghent, Belgium (GRID:grid.510942.b); Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 Cancer Research Institute Ghent (CRIG), Ghent, Belgium (GRID:grid.510942.b); Ghent University Hospital, Department of Pathology, Ghent, Belgium (GRID:grid.410566.0) (ISNI:0000 0004 0626 3303) 
 University of Cologne, Department for Experimental Pediatric Oncology, and Center for Molecular Medicine Cologne (CMMC), Medical Faculty, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777) 
 Memorial Sloan Kettering Cancer Center, Department of Pediatrics, New York, USA (GRID:grid.51462.34) (ISNI:0000 0001 2171 9952) 
 Charité-Universitätsmedizin Berlin, Department of Pediatric Oncology and Hematology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662) 
 Lund University, Department of Immunotechnology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
 Academic Medical Center, Department of Oncogenomics, Amsterdam, The Netherlands (GRID:grid.5650.6) (ISNI:0000000404654431) 
Pages
1267
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2784121945
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.